KBC Group’s Fulgent Genetics FLGT Stock Holding History

KBC Group’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-700	Closed	-$15K	–	1870
2024 Q1	$15K	Hold	700	–	–	﹤0.01%	1840
2023 Q4	$20K	Sell	700 -264	-27%	-$7.06K	﹤0.01%	1853
2023 Q3	$26K	Sell	964 -560	-37%	-$19.1K	﹤0.01%	1838
2023 Q2	$56K	Sell	1,524 -185	-11%	-$6.45K	﹤0.01%	1342
2023 Q1	$53K	Hold	1,709	–	–	﹤0.01%	1369
2022 Q4	$51K	Hold	1,709	–	–	﹤0.01%	1384
2022 Q3	$65K	Hold	1,709	–	–	﹤0.01%	1322
2022 Q2	$93K	Buy	+1,709	New	+$93.9K	﹤0.01%	1251
2022 Q1	–	Sell	-3,355	Closed	-$337K	–	1279
2021 Q4	$337K	Hold	3,355	–	–	﹤0.01%	960
2021 Q3	$302K	Sell	3,355 -3,969	-54%	-$361K	﹤0.01%	992
2021 Q2	$676K	Buy	7,324 +6,010	+457%	+$480K	﹤0.01%	993
2021 Q1	$126K	Buy	+1,314	New	+$136K	﹤0.01%	1227

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

KBC Group's FLGT Position: Q2 2024 in Review

KBC Group sold out of Fulgent Genetics (FLGT) in Q2 2024, closing a stake of 700 shares — an estimated $15K sold.

KBC Group first reported a position in FLGT in Q1 2021 and held it in 12 quarters. The position peaked at $676K in Q2 2021. 173 funds tracked by Wall St. Rank hold FLGT as of Q2 2024.

KBC Group reported no remaining Fulgent Genetics position as of Q2 2024 after selling out during the quarter.
KBC Group sold 700 Fulgent Genetics shares in Q2 2024, an estimated $15K.
KBC Group first reported a position in Fulgent Genetics in Q1 2021 and held it in 12 quarters.
KBC Group's Fulgent Genetics position peaked at $676K in Q2 2021.
173 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.